Figure 1.

Creation of Galgt2 transgenic α sarcoglycan-deficient (Sgca^−/−) mice. A: Galgt2 transgenic (CT) mice and non-transgenic littermates that were either heterozygous (Sgca^+/−) or homozygous (Sgca^−/−) for a deletion of α sarcoglycan were stained with a monoclonal antibody to α sarcoglycan or with CT2, an antibody that recognizes the CT carbohydrate. Control secondary antibody for CT2 (IgM only) and α sarcoglycan (IgG only) are also shown. Scale bar = 100 μm. B: 40 μg of whole muscle SDS protein lysate was blotted for Galgt2 protein and for α sarcoglycan protein. Actin was used as a control for protein loading and transfer. Asterisk indicates native molecular weight for the protein of interest. C: Sgca^+/−CT and Sgca^−/−CT muscles show similar increases in Galgt2 mRNA, relative to Sgca^+/− and Sgca^−/−, respectively, as measured by quantitative RT-PCR. D: Galgt2 mRNA was reduced in Sgca^−/− muscles relative to Sgca^+/−. Gas, gastrocnemius; Quad, quadriceps; TA, tibialis anterior; Tri, triceps; Dia, diaphragm. Errors are SD for 3 to 4 animals per condition (in C and D).